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Purpose: This study evaluated the cytotoxicity of five prostaglandin analog ophthalmic 
  solutions on four ocular surface cell lines, ie, Chang (human conjunctiva), SIRC (rabbit cornea), 
RC-1 (rabbit cornea), and BCE C/D-1b (bovine cornea).
Methods: Cell viability was measured by neutral red and MTT assays in cells treated for 
10, 30, or 60 minutes with various doses of prostaglandins (undiluted, and 2- and 10-fold 
dilutions). The number of cell lines with viability $50% in the presence of selected dilution 
of the drug (CVS50) was used for comparison. In addition, 24 cell viability comparisons (four 
cell lines, two assays, and three exposure times) were made between latanoprost (Xalatan®) 
and each other solution at each dose. A comparison between the newly introduced tafluprost 
(Tapros®) with 0.01% benzalkonium chloride was also made.
Results: The order of cell viability determined by CVS50 was Travatan Z® (travoprost with the 
SofZia system) . Tapros $ Travatan® (travoprost) = Xalatan . Rescula® (unoproston). This 
was consistent with the results of direct comparisons between Xalatan and the other drugs. There 
was no clear difference in cell viability between Tapros and benzalkonium chloride.
Conclusions: Use of two assays, multiple cell lines, and various dilutions and exposure times 
provided a unique evaluation of cytotoxicity among ophthalmic solutions. CVS50 was useful 
for comparison of the cell viability of the solutions.
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Introduction
Prostaglandin analogs (PGs) form a major part of treatment regimens for glaucoma.1 
PGs successfully reduce ocular pressure,2–5 with few common side effects including 
conjunctival hypernemia6–8 and increased iris pigmentation.9–13 Cytopathic evaluations 
of PGs in conjunctival cells14–18 have indicated that latanoprost (Xalatan®) and travo-
prost (Travatan®) could be cytoprotective against benzalkonium chloride toxicity via an 
antioxidative effect.15 Benzalkonium chloride is commonly included as a preservative 
in ophthalmic solutions,19–21 although Travatan Z® (also travoprost) is preserved with 
a SofZia system that has proven to be less cytotoxic.21 Among the PGs, Xalatan was 
introduced early and has become a standard medication. Tafluprost (Tapros®)16,22,23 is 
a recently introduced PG and the cytotoxicity of preserved tafluprost is untested. We 
therefore evaluated the cytotoxicity of Tapros compared with that of five other PG 
ophthalmic agents in four corneoconjunctival cell lines using two cytotoxic assays 
to compare Xalatan with other available PG drugs, test for intercellular or interas-
say differences in toxicity, and to determine the optimal dose and exposure time for 
cytotoxic testing.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Materials and methods
The cell lines used in the present study were SIRC (rab-
bit   corneal epithelium, CCL-60, American Type Culture 
  Collection [ATCC], Manassas, VA), BCE C/D-1b (bovine 
corneal epithelial cells, JCRB-9129, Health Science Research 
Resource Bank, Osaka, Japan), RC-1 (rabbit corneal 
  epithelium, JCRB-0246; Health Science Research Resource 
Bank), and Chang conjunctiva (human conjunctival cells, 
ATCC CCL-20.2). All cell lines were cultured according to 
the standard protocols provided by the suppliers.
Approximately 2 × 104 cells were harvested from 96-well 
culture plates (NUNC® 167008; Thermo Fisher Scientific, 
Denmark) and incubated for two days. The culture medium was 
then replaced with undiluted, twofold, or 10-fold dilutions of 
the different ophthalmic drugs, and the cells were incubated for 
a further 10, 30, or 60 minutes. After these drug treatments, the 
culture medium was replaced with fresh media and cells were 
incubated for a further 48 hours. Cell viability was determined 
using 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium 
bromide (MTT) and neutral red assays. The MTT assay is a 
quantitative colorimetric assay of mitochondrial activity as a 
measure of cell viability and proliferation; it detects living cells 
only, and the signal generated is directly proportional to the 
number of viable cells. In contrast, neutral red staining lyso-
somes in living cells and the results of the assay are determined 
spectrophotometrically (Benchmark Microplate Reader; BIO-
RAD, Hercules, CA). Cell viability of treated cells is expressed 
as a percentage of that in control cells (incubated in culture 
medium alone). All experiments were repeated 8–16 times 
and results are presented as the mean ± standard deviation 
(SD). Statistical comparisons were made using the t-test by 
Microsoft Excel (Microsoft, Tokyo, Japan), and P , 0.05 was 
determined as significant.
We compared cell viability using the cell viability score. 
In a previous study,24 we used CVS50 (ie, number of cell lines 
with viability $ 50% in the presence of a selected dose of the 
drug) to enable easy comparison of the effects of different 
drugs, and found it was useful. This concept is similar to that 
of the MIC50 (ie, the minimum inhibitory concentration of a 
drug required to inhibit the growth of 50% of organisms). In 
addition, 24 comparisons of cell viability (four corneal cell 
lines, two assays, and three exposure times) were also made 
between Xalatan, a leading PG and serving as the standard, 
and each other solution at each dose. A comparison between 
Tapros and 0.01% benzalkonium chloride was also made.
We used the following solutions for cytotoxicity: 
0.0015% Tapros (with 0.01% benzalkonium chloride and 
polysorbate 80), 0.005% Xalatan (with 0.02% benzalko-
nium chloride), 0.12% unoproston (Rescula®, with 0.005% 
benzalkonium chloride), 0.004% travoprost (Travatan, 
with 0.015% benzalkonium chloride), 0.004% travoprost 
  (Travatan Z), and 0.01% benzalkonium chloride.
Results
Figures 1–4 show the cell viability results for four cell 
lines, and its order determined by CVS50 was Travatan 
Z $ Tapros $ Travatan = Xalatan . Rescula (Table 1). 
Table 2 details the comparison between Xalatan and the other 
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Figure 1 effects of prostaglandin analog ophthalmic solutions on the viability of cultured rabbit corneal cells (rC-1) using the neutral red (nr) assay and MTT assay. Data 
are means ± standard deviations. note that Travatan Z exhibits the greatest viability and shows minimal differences among exposure times or dilution. The cell viabilities for 
the other solutions depend on exposure times and dilutions except for Rescula, which shows small cell viabilities even in diluted solutions. These are common findings in all 
cell lines. Detailed comparisons were made with cell viability score and statistical analysis (Tables 1–3).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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drugs for all cell lines. Based on these results, cell viability 
was clearly the highest for Travatan Z, with only small 
changes seen among different dilutions and exposure times. 
In contrast, it was the lowest for Rescula. CVS50 expressed 
general trend of graphic presentation and detailed   comparison 
was consistent with CVS50. The comparison between Travatan 
and Xalatan only exhibited conflicting results in three doses, 
although those two drugs had the same CVS50.
The comparison of Tapros and 0.01% benzalkonium 
chloride (Table 3) indicated that cell viability in benzalkonium 
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Figure 2 effects of prostaglandin analog ophthalmic solutions on the viability of cultured rabbit corneal cells (sIrC) using the neutral red (nr) assay and MTT assay. Data 
are means ± standard deviations.
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Figure 3 effects of prostaglandin analog ophthalmic solutions on the viability of cultured bovine corneal cells (BCe C/D 1-b) using the neutral red (nr) assay and MTT assay. 
Data are means ± standard deviations.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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chloride was always higher with the 10-minute treatments 
(8/8 experiments), but was not different (3/8) or was lower 
(5/8) in benzalkonium chloride after a 30-minute exposure. 
There was no difference in cell viability between Tapros and 
benzalkonium chloride with the 60-minute exposure.
The MTT and neutral red assays produced comparable 
results and there were no conflicting results in any com-
parisons. The MTT values were generally less than those 
obtained with the neutral red assay, especially in undiluted 
and twofold diluted solutions. There were also no major 
inconsistencies among results from the four cell lines, as 
shown in Figures 1–4.
Discussion
Benzalkonium chloride concentration in the various ophthalmic 
solutions tested in this study increased in the following order: 
Travatan Z , Rescula , Tapros ,   Travatan ,   Xalatan. 
This increase was inversely in accordance with cell viability, 
except for Rescula, which was more toxic than Travatan and 
Tapros with more benzalkonium chloride. Unoproston in 
Rescula is a metabolized form of natural PG F2 alpha and 
is different from the other PGs, although this study did not 
address whether the difference in cytotoxicity is related to 
this unique structure. The cytotoxicity of preserved tafluprost 
was first examined in vitro and proved comparable with 
Xalatan and Travatan. Considering Tapros contains toxic 
levels of benzalkonium chloride and polysorbate 80, the 
lower cell viability observed in this study after 10 minutes 
of exposure compared with benzalkonium chloride alone in 
all cell lines was not unexpected. Although cell viability in 
Tapros was greater than or equal to that in 0.01% benzalko-
nium chloride in some of comparisons, the cytoprotective 
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Figure 4 effects of prostaglandin analog ophthalmic solutions on the viability of cultured human conjunctival cells (Chang) conjunctiva using the neutral red (nr) assay and 
MTT assay. Data are means ± standard deviations. Travatan Z exhibited a proliferative effect (cell viability . 100%) with the 10-fold dilution.
Table 1 Cell viability score of the drugs
Drugs Fold dilution and exposure time (min) Total of CVS50
1 ×  2 × 10 ×
10 30 60 10 30 60 10 30 60
Xalatan 0 0 0 0 0 0 8 8 7 23
rescula 0 0 0 0 0 0 4 2 1 7
Travatan 0 0 0 1 0 0 8 7 7 23
Travatan Z 8 8 8 8 8 8 8 8 8 72
Tapros 0 0 0 6 2 0 8 8 8 32
Notes: The full number of assay is eight (four cell lines × two assays for each time and dilution). 
Abbreviations: CVs50, number of cell lines with viability $50% in the presence of the drug; min, minutes.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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effect of tafluprost on ocular surface cell lines was unclear 
in our experiments.
We evaluated cell viability for multiple conditions using 
two bioassays. The undiluted and twofold diluted solu-
tions seemed suitable for clinically relevant comparisons 
of cytotoxicity, possibly because these represent levels that 
are s  timulatory immediately after instillation. The 10-fold 
dilutions were not practical in this experimental setting, but 
could be useful in testing of long-term cytotoxicity after 
diluted by tears. The 10-minute exposure time represented 
actual   residence time of the applied solution on an ocular 
surface and seemed to be the minimum period required 
for in vitro testing. Our results were similar between the 
10- and 30-minute exposures, although the latter was deemed 
more convincing and clinically applicable. The differences 
between the drugs reduced in significance after 60 minutes 
of exposure due to the low viability rates. It should be noted 
that this experiment would not be correlated with pressure 
reduction effects that work around the intraocular tissue 
and last for several hours. As for assays and cells, the MTT 
assay values were very low in some experiments; however, 
there were no discrepant comparisons with neutral red 
assay results. CVS50 was simple and useful to compare cell 
viability in tested solutions and was confirmed by detailed 
comparisons. We believe bioassay using multiple cell lines 
is a contributory method to precise results. CVS50 might be 
applicable to such toxicity experiments.
This study had some limitations. Although we used two 
different assays and tested four cell lines, the bioassay only 
evaluated cytotoxicity, thus the results should be confirmed 
using a series of methods. Second, toxicity of the PGs for 
keratoconjunctival cells was not evaluated directly, although 
the active component and preservative could potentially 
interact in the commercial eyedrop mixture. Multiple evalu-
ations should be done to investigate the potential side effects 
of PGs in glaucoma patients further.
Table 2 Comparison of cell viability between Xalatan and other prostaglandins
Drugs and comparison results Summary of comparisons for each exposure time and fold dilution
1 ×  2 ×  10 ×
10 30 60 10 30 60 10 30 60
rescula .Xalatan* 0 1 0 0 0 0 0 3 0
ns* 5 6 7 8 8 7 6 2 1
,Xalatan* 3 1 1 0 0 1 2 3 7
Travatan .Xalatan 4 2 2 6 6 3 0 0 0
ns 4 6 5 2 2 5 4 4 3
,Xalatan 0 0 1 0 0 0 4 4 5
Travatan Z .Xalatan 8 8 8 8 8 8 4 5 3
ns 0 0 0 0 0 0 4 2 4
,Xalatan 0 0 0 0 0 0 0 1 1
Tapros .Xalatan 4 1 0 7 6 3 3 2 2
ns 4 6 7 1 2 4 4 5 5
 
,Xalatan 0 1 1 0 0 1 1 1 1
Notes: each comparison includes eight experiments (two assays for four cell lines); *P , 0.05 (result of t-test). 
Abbreviation: NS, not significant.
Table 3 Comparison of cell viability between undiluted Tapros and 0.01% BAK
Cell lines Exposure time for neutral red assay Exposure time for MTT assay
10 min 30 min 60 min 10 min 30 min 60 min
sIrC Tapros 26.1 ± 12.7 14.4 ± 8.0 9.6 ± 1.4 16.7 ± 11.8 3.9 ± 1.1* 4.0 ± 1.3
BAK 58.2 ± 19.8** 13.8 ± 7.1 8.1 ± 3.0 37.5 ± 5.8** 2.4 ± 0.7 3.8 ± 3.4
rC-1 Tapros 9.2 ± 3.6 9.1 ± 4.6 7.3 ± 1.2 3.5 ± 0.2 3.5 ± 0.9 4.3 ± 1.4
BAK 30.2 ± 5.6** 6.8 ± 0.3 7.0 ± 0.4 26.4 ± 14.8** 3.7 ± 0.3 4.3 ± 0.7
BCe Tapros 18.2 ± 9.2 11.5 ± 8.6 7.3 ± 2.2 11.9 ± 11.1 2.4 ± 1.2 2.8 ± 1.8
BAK 49.8 ± 20.8** 7.4 ± 0.6 7.5 ± 0.6 33.3 ± 6.9** 1.5 ± 0.5 1.7 ± 0.2
Chang  
Conjunctiva
Tapros 11.2 ± 5.9 12.0 ± 5.6* 11.0 ± 4.6 3.4 ± 1.8 2.6 ± 0.6* 2.7 ± 1.2
BAK 20.4 ± 3.6** 7.0 ± 0.7 7.5 ± 1.6 14.0 ± 3.8** 2.0 ± 0.2 2.1 ± 0.3
Notes: *Tapros-treated cells show greater viability (P , 0.05, t-test); **BAK is greater (P , 0.05, t-test).
Abbreviations: BAK, benzalkonium chloride; min, minute. Clinical Ophthalmology
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Conclusion
Using two cytotoxicity assays on four ocular surface cell 
lines with a series of dilutions and exposure times of test 
PG ophthalmic solutions enabled a unique evaluation of 
cytotoxicity. The results confirmed that Travatan Z without 
benzalkonium chloride is the least toxic drug among the 
ocular surface cells tested. The detailed drug comparison 
included the newly available preserved Tapros and the order 
of cell viability rate was determined accordingly. Optimal 
exposure times and dilutions for cytotoxicity testing of oph-
thalmic solutions were also discussed. CVS50 was useful for 
comparison of cell viability in the drugs.
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